Key result
Statins show therapeutic benefit for NAFLD but mevalonate pathway inhibition risks inducing myopathy.
Why the study?
Statins show therapeutic potential in NAFLD, but their use is controversial due to statin-associated muscle symptoms leading to non-adherence or discontinuation.
This review highlights the therapeutic potential of statins in NAFLD management and discusses the molecular mechanisms and mitigation strategies for statin-induced myopathy.
Answers are grounded in this paper and cite their sources.
Supports statin evaluation in NAFLD trials; leaves open safe implementation amid myopathy risks.
Non-alcoholic fatty liver disease (NAFLD) encompasses a range of hepatic disorders characterized by excessive lipid accumulation in hepatocytes and is closely linked to metabolic syndrome. Statins, which are potent lipid-lowering agents, have emerged as potential therapeutic options for managing NAFLD. Recent meta-analyses have demonstrated the efficacy of statins in reducing liver enzymes, improving histological features, and attenuating disease progression in patients with NAFLD. Mechanistically, statins exert their beneficial effects by inhibiting cholesterol synthesis, modulating lipid metabolism, and exhibiting anti-inflammatory and antifibrotic properties. They target key pathogenic pathways in NAFLD, including the inhibition of sterol regulatory element-binding proteins (SREBPs), activation of peroxisome proliferator-activated receptor-alpha (PPAR-α), and enhancement of fatty acid β-oxidation. Additionally, statins mitigate hepatic inflammation by reducing pro-inflammatory cytokines and oxidative stress, while promoting fibrosis regression through the inhibition of RhoA/Rho kinase signaling and transforming growth factor-beta (TGF-β) pathways. However, statin-associated muscle symptoms (SAMS) remain a significant concern, often leading to treatment non-adherence or discontinuation. The molecular mechanisms underlying statin-induced myopathy involve the inhibition of the mevalonate pathway, coenzyme Q10 depletion, mitochondrial dysfunction, and disruption of the ubiquitin-proteasome system. Strategies to prevent and manage SAMS include alternative dosing regimens, statin switching, and the use of complementary therapies such as coenzyme Q10 and vitamin D supplementation. Novel approaches, including PCSK9 inhibitors and nutraceuticals, have also shown promise in mitigating statin-related muscle adverse effects. In conclusion, statins offer a promising therapeutic avenue for NAFLD management, particularly in patients with elevated cardiovascular risk. This review updated the statins' therapeutic potential in NAFLD, their molecular mechanisms, statin-induced myopathy, extra-hepatic effects, and preventive strategies for future research. • Statins in NAFLD offer benefits beyond cholesterol-lowering therapy. • Statins target NAFLD pathogenesis by inhibiting SREBPs, activating PPAR-α, enhancing fatty acid β-oxidation, and reducing oxidative stress and pro-inflammatory cytokines. • Statin use in NAFLD is controversial due to the risk of statin-induced myopathy. • Statin-induced myopathy arises from mevalonate pathway inhibition, CoQ10 depletion, mitochondrial dysfunction, and disruption of the ubiquitin-proteasome system. • Strategies to mitigate myopathy may enhance statin efficacy in NAFLD treatment.
No takes yet. Share an insight, caveat, or question.
Nanepag et al. (2025) conducted a review in Non-alcoholic fatty liver disease (NAFLD). Statins was evaluated. Statins offer therapeutic benefits for NAFLD by targeting pathogenic pathways, though their clinical use is complicated by statin-induced myopathy arising from mevalonate pathway inhibition.
Synapse has enriched 10 related papers. Consider them for comparative context: